by Cary Miller | Apr 24, 2017 | Final Written Decisions, Pharmaceutical
By Unmesh Shah, Ph.D. and Cary Miller, Ph.D. Allergan is typically the patent holder in these types of disputes, however, it recently successfully played the role of petitioner in an IPR against 1474791 Ontario Ltd.’s U.S. Patent No. 6,806,251 covering the use of...
by Jones Day's PTAB Team | Apr 20, 2017 | Pharmaceutical
By Wanli Tang, Ph.D. and J. Patrick Elsevier, Ph.D. The PTAB issued a final written decision in IPR2016-00204, upholding the validity of claims 1–13 of Patent RE38,551 E (“the ’551 patent”), which covers the antiepileptic drug VIMPAT® (lacosamide). The petitioner,...
by Jones Day's PTAB Team | Apr 7, 2017 | Amendment Practice, Pharmaceutical
By Lisamarie LoGiudice, Ph.D. and J. Patrick Elsevier, Ph.D. In Amerigen Pharmaceuticals Limited v. Shire LLC, IPR2015-02009 (March 31, 2017), the PTAB granted Shire’s Motion to Amend the claims in U.S. Reissued Patent RE 42,096, listed in the FDA’s Orange Book as...
by Cary Miller | Mar 30, 2017 | Final Written Decisions, Pharmaceutical
By Olga Schwier, Ph.D. and Cary Miller, Ph.D. The PTAB found obvious all claims of U.S. Patent Nos. 7,582,621 and 7,767,657 in the three final written decisions issued on February 23, 2017 (IPR2015-01776, IPR2015-01780, and IPR2015-01785). This marks another victory...
by Cary Miller | Mar 24, 2017 | Pharmaceutical, Prior Art Issues
By Jeff Giering, Ph.D. and Cary Miller, Ph.D. On March 6, 2017, the PTAB issued a pair of final written decisions upholding the patentability of U.S. Patent Nos. 7,932,268 (IPR2015-01836) and 8,618,135 (IPR2015-01835), in challenges filed by the Coalition for...
by Cary Miller | Mar 21, 2017 | Pharmaceutical
By Bing Liang, Ph.D. and Cary Miller, Ph.D. On February 28, 2017, the PTAB held that the petitioner Lupin had not shown that the challenged claims in two of Pozen’s patents were invalid (IPR2015-01773 and IPR2015-01775). These cases show the advantage of using...
